Professor Andreas Bender

Currently also: Chief Informatics and Technology Officer (CITO) at Pangea Botanica, London/UK and Berlin/Germany

Previous positions:

Director Digital Chemistry at NUVISAN Berlin

Associate Director Computational ADME and Safety (Clinical Pharmacology & Safety Sciences/Data Science and Artificial Intelligence - CPSS/DSAI) at AstraZeneca Cambridge

Co-founder of Healx Ltd.

Co-founder of PharmEnable Ltd.

Personal Website

Committed to developing new life science data analysis methods (AI/ML/data science) and their application, primarily related to chemical biology, drug discovery and in silico toxicology
Expertise comprises data ranging from chemical structure and gene expression data to phenotypic readouts and preclinical information, applied to both efficacy- and safety/tox-related questions
Collaborating with academic research groups, as well as pharmaceutical, chemical, and consumer goods companies (Eli Lilly, AstraZeneca, GSK, BASF, Johnson&Johnson/Janssen, Unilever, ...)
Co-founder/founding CTO and current SAB member of Healx Ltd. (data-driven drug repurposing for rare diseases, and beyond); co-founder of PharmEnable Ltd.; SAB member of Lhasa Ltd. (toxicology and metabolism prediction) and Cresset Ltd.
Coordinator of the Computational & In Silico Toxicology Specialty Section of the British Toxicology Society (BTS)
Steering Committee Member of the Cambridge Alliance on Medicines Safety (CAMS)
Currently leading a group of ca. 15 PhD students, postdocs, project students and visitors at the Centre for Molecular Informatics at the University of Cambridge, https://www-cmi.ch.cam.ac.uk/centre-molecular-informatics

Publications

Prediction of synergistic drug combinations

ZB Weinstein, A Bender, M Cokol

Current Opinion in Systems Biology

(2017)

(doi: 10.1016/j.coisb.2017.05.005)

Towards understanding polyol additive effects on the pH shift-induced aggregation of a monoclonal antibody using high throughput screening and quantitative structure-activity modeling

O-O Oyetayo, O Méndez-Lucio, A Bender, H Kiefer

International journal of pharmaceutics

(2017)

530

165

(doi: 10.1016/j.ijpharm.2017.07.059)

Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat

G Drakakis, KA Wafford, SC Brewerton, MJ Bodkin, DA Evans, A Bender

ACS Chem Biol

(2017)

1593

(doi: 10.1021/acschembio.7b00209)

Drug Repurposing Review

D Cavalla, E Oerton, A Bender

(2017)

1-8

(doi: 10.1016/b978-0-12-409547-2.12283-8)

Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists.

AM Bender, RL Weiner, VB Luscombe, S Ajmera, HP Cho, S Chang, X Zhan, AL Rodriguez, CM Niswender, DW Engers, TM Bridges, PJ Conn, CW Lindsley

Bioorganic & Medicinal Chemistry Letters

(2017)

3576

(doi: 10.1016/j.bmcl.2017.05.042)

Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.

DJ Mason, I Stott, S Ashenden, ZB Weinstein, I Karakoc, S Meral, N Kuru, A Bender, M Cokol

J Med Chem

(2017)

3902

(doi: 10.1021/acs.jmedchem.7b00204)

Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.

CP Baburajeev, CD Mohan, S Rangappa, DJ Mason, JE Fuchs, A Bender, U Barash, I Vlodavsky, Basappa, KS Rangappa

BMC cancer

(2017)

235

(doi: 10.1186/s12885-017-3214-8)

Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson's disease: A comparison of 33 human and animal studies

E Oerton, A Bender

BMC Neurology

(2017)

(doi: 10.1186/s12883-017-0838-x)